Watch SONM. Know when insiders buy.
One email the day a filing lands. Free.
SONM
DNA X, Inc.
4.30
+0.39 +9.96%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$8.5MNET DEBT $172K52W 2.75 – 16.87SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.3M | −$1.2M | — | -0.92 | −$2M | — | — | Aug 19 |
| Q1 2026 · Mar 31 | — | — | — | −$3.6M | $6.3M | +1284.3% | 5.01 | −$3.5M | — | — | May 20 |
| Q4 2025 · Dec 31derived | — | — | — | $4.7M | −$8.9M | — | -9.44 | −$2M | — | — | Apr 15 |
| Q3 2025 · Sep 30 | $16.2M | +7.9% | 11.2% | −$4M | −$4.8M | — | -4.83 | −$7M | — | — | Oct 31 |
| Q2 2025 · Jun 30 | $11.2M | −2.8% | 7.6% | −$1.5M | −$7.5M | — | -14.15 | −$4.9M | — | — | Aug 19 |
| Q1 2025 · Mar 31 | $16.7M | −0.3% | 50.0% | −$870K | $458K | — | 1.41 | −$9.6M | — | — | May 20 |
| Q4 2024 · Dec 31derived | $15M | +11.6% | -1.2% | $8.4M | −$21.6M | — | -81.87 | −$4.5M | $8K | −$4.5M | Apr 15 |
| Q3 2024 · Sep 30 | $15M | −45.5% | 28.2% | −$2.4M | −$2.5M | −576.7% | -9.32 | −$417K | $137K | −$554K | Oct 31 |
| Q2 2024 · Jun 30 | $11.5M | — | 25.8% | −$6.5M | −$6.6M | — | -1.41 | −$3.4M | $39K | −$3.4M | Aug 8 |
| Q1 2024 · Mar 31 | $16.8M | — | 17.3% | −$2.7M | −$2.9M | — | -0.65 | −$168K | $30K | −$198K | May 12 |
| Q4 2023 · Dec 31derived | $13.4M | — | 38.1% | −$1.3M | −$1.4M | — | -0.31 | −$351K | $12K | −$363K | Mar 31 |
| Q3 2023 · Sep 30 | $27.6M | — | 20.3% | $688K | $527K | — | 0.12 | −$304K | $1K | −$305K | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$5.4M | −$20.7M | — | -28.58 | −$23.5M | — | — | — | — |
| FY2024 · to Dec 31 | $58.3M | 17.0% | −$3.1M | −$33.6M | -57.7% | -128.37 | −$8.5M | $214K | −$8.7M | — | — |
| FY2023 · to Dec 31 | $93.6M | 20.6% | $513K | −$90K | -0.1% | -0.02 | −$4.1M | $36K | −$4.1M | — | — |
| FY2022 · to Dec 31 | $69.8M | 16.6% | −$14.3M | −$14.1M | -20.2% | -0.49 | −$12.4M | $8K | −$12.4M | — | — |
| FY2021 · to Dec 31 | $54.6M | 11.8% | −$38M | −$38.6M | -70.8% | -4.08 | −$38.5M | $46K | −$38.5M | — | — |
| FY2020 · to Dec 31 | $64M | 23.8% | −$29.3M | −$29.9M | -46.8% | -6.48 | −$10.6M | $11K | −$10.6M | — | — |
Every number comes from DNA X, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.